NewsRx

Search our medical news database

Finance

EvoGenix offered $1.6 million grant for cancer drug program

Published in Cancer Weekly, August 8th, 2006

Antibody therapeutics company EvoGenix Limited (EGX) announced that it had been offered a grant of $1.66 million to fast track development of its anti-cancer antibody, DMF10.

The grant will be provided over two years under the Australian Government's Commercial Ready program, a competitive merit-based grant program supporting innovative product research and development.

DMF10 is a hamster antibody which has shown strong evidence of activity against lung cancer and melanoma. The antibody attacks a structure on the surface of cancer cells that is not found on normal cells, creating a cancer therapy that is potentially both effective and devoid of...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook